Stepan Company SCL · NYSE
$69.62 -0.54% (-$0.38)
Summary
41 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 12 years in a row.
- It has been profitable 6 years in a row.
What to watch
- Earnings per share fell by 32% a year over the last 3 years.
- It pays out more in dividends than it earns: 830% of profit.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 0.2 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 367.6 USD for 1 USD of yearly profit. Over the last five years it was 28.8 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 4.5% a year over 5 years. Over the last 3 years it fell by 5.6% a year. Earnings per share fell by 32% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 88 USD
- Research and development 2.5 USD
- Sales and administration 6.1 USD
- Taxes and other 3.2 USD
- Net profit 0.2 USD
Net profit, industry median (Chemicals - Specialty) 6.0 USD
Out of every 100 USD of revenue, 0.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.26%
- Paid out of profit
- 830%
- Raised in a row
- 12 years
You receive $1.58 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $85 is 22% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Surfactants 71%
- Polymers 25%
- Specialty Products 3.5%
By region
- North America 57%
- Europe 23%
- Latin America 15%
- Asia 4.0%
Surfactants brings in 71% of revenue. Polymers grew fastest, by 5.3% a year.
Segments in detail